The estimated Net Worth of Michael Hunkapiller is at least $72 Milion dollars as of 26 February 2021. Michael Hunkapiller owns over 234,246 units of Pacific Biosciences of California Inc stock worth over $1,818,854 and over the last 14 years he sold PACB stock worth over $69,273,009. In addition, he makes $859,188 as Director at Pacific Biosciences of California Inc.
Sign up
Michael Hunkapiller PACB stock SEC Form 4 insiders trading
Michael has made over 26 trades of the Pacific Biosciences of California Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 234,246 units of PACB stock worth $1,489,805 on 26 February 2021.
The largest trade he's ever made was selling 1,950,000 units of Pacific Biosciences of California Inc stock on 10 November 2020 worth over $28,840,500. On average, Michael trades about 259,525 units every 97 days since 2010. As of 26 February 2021 he still owns at least 1,082,651 units of Pacific Biosciences of California Inc stock.
You can see the complete history of Michael Hunkapiller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Hunkapiller biography
Dr. Michael W. Hunkapiller Ph.D. has been appointed as Director of the Company effective 9/14/2020. He was Chairman of our Board of Directors from 2011 until March 2, 2020 and has served on our Board of Directors since 2005. Since November 2004, Dr. Hunkapiller has been a General Partner at Alloy Ventures, or Alloy, a venture capital firm. Prior to Alloy, Dr. Hunkapiller spent 21 years at Applied Biosystems Inc. At Applied Biosystems, he held various positions, most recently serving as president and general manager. Dr. Hunkapiller holds a Ph.D. in Chemical Biology from the California Institute of Technology and a B.S. in Chemistry from Oklahoma Baptist University. Hunkapiller possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his long history with us, as well as his extensive experience at Applied Biosystems.
What is the salary of Michael Hunkapiller?
As the Director of Pacific Biosciences of California Inc, the total compensation of Michael Hunkapiller at Pacific Biosciences of California Inc is $859,188. There are no executives at Pacific Biosciences of California Inc getting paid more.
How old is Michael Hunkapiller?
Michael Hunkapiller is 71, he's been the Director of Pacific Biosciences of California Inc since 2020. There are 2 older and 16 younger executives at Pacific Biosciences of California Inc. The oldest executive at Pacific Biosciences of California Inc is Lucy Shapiro, 79, who is the Independent Director.
What's Michael Hunkapiller's mailing address?
Michael's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Insiders trading at Pacific Biosciences of California Inc
Over the last 14 years, insiders at Pacific Biosciences of California Inc have traded over $95,441,111 worth of Pacific Biosciences of California Inc stock and bought 2,252,330 units worth $6,097,136 . The most active insiders traders include Michael Hunkapiller, John F Milligan a Christian O Henry. On average, Pacific Biosciences of California Inc executives and independent directors trade stock every 44 days with the average trade being worth of $202,112. The most recent stock trade was executed by Jeff Eidel on 19 August 2024, trading 26,760 units of PACB stock currently worth $42,548.
What does Pacific Biosciences of California Inc do?
pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
What does Pacific Biosciences of California Inc's logo look like?
Complete history of Michael Hunkapiller stock trades at Pacific Biosciences of California Inc
Pacific Biosciences of California Inc executives and stock owners
Pacific Biosciences of California Inc executives and other stock owners filed with the SEC include:
-
Michael Hunkapiller,
Director -
Christian O. Henry M.B.A.,
Pres, CEO & Director -
Susan G. Kim,
Chief Financial Officer -
Dr. Denis Zaccarin Ph.D.,
Sr. VP of R&D -
William Ericson,
Independent Director -
Randall Livingston,
Independent Director -
Marshall Mohr,
Independent Director -
John Milligan,
Independent Chairman of the Board -
Lucy Shapiro,
Independent Director -
Kathy Ordonez,
Director -
Christian Henry,
President, Chief Executive Officer, Director -
David Botstein,
Independent Director -
Susan Kim,
Chief Principal Officer, Chief Accounting Officer -
Eric Schaefer,
Chief Accounting Officer, Vice President -
Denis Zaccarin,
Vice President - Semiconductor Integration Devices -
Chris Seipert,
Vice President, Sales, Service & Support, EMEA and America -
Kathleen Lynch J.D.,
Head of Global Gov. Affairs & Corp. Communications -
Michele Farmer CPA,
VP & Chief Accounting Officer -
Kathleen Lynch,
Head of Global Gov. Affairs & Corp. Communications -
Brett Atkins J.D., Ph.D.,
Gen. Counsel & Corp. Sec. -
Trevin Rard,
Head of Investor Relations -
Dr. Jonas Korlach Ph.D.,
Chief Scientific Officer -
Michele Farmer,
VP & Chief Accounting Officer -
Mark Van Oene,
Chief Operating Officer -
Dr. Stephen Turner,
Co-Founder & CTO -
James Michael Phillips,
SVP, Research & Development -
Susan K Barnes,
EVP, CFO and PAO -
Kevin P Corcoran,
SVP, Market Development -
Brook H Byers,
Director -
Jeff Eidel,
See Remarks -
Brian B Dow,
VP and PAO -
Michael Glynn,
Chief Commercial Officer -
David B Singer,
Director -
Susan E Siegel,
Director -
Hugh C Martin,
Chairman, CEO & President -
Stephen W Turner,
VP & Chief Technology Officer -
Hannah Valantine,
Director -
Oene Mark Van,
See Remarks -
Peter Fromen,
See Remarks -
Michele Farmer,
See Remarks -
David W Meline,
Director